| *Sponsored
Biotech Alert (Nasdaq: CMMB) Is Developing Innovative Therapeutics (4 Potential Catalysts)
March 27th Greetings, Friend!
Talk about a smoking-hot two day stretch!
First off, I need to recap my NYSE American profile alerted for Tuesday AM.
From an open of $1.66 on 3/25, that breakout idea has now completed a surge all the way to $2.41 as of Wednesday's closing bell.
Overall, that's an explosive move of approx. 45% over a short 2 day stretch.
Wednesday's profile was no slouch either.
Running from an approximate 9:45AM EST valuation of $4.10, that Nasdaq profile popped approx. 13% intraday.
But we're not here trying to live in the past, we're ready to look forward to the future and what's next.
And that next thing is a Nasdaq biotech company making serious moves while still maintaining anonymity under Wall Street's radar.
Mix in a relatively low float under 17Mn shares, a $7.00 analyst target, and strong news early in 2025, and that anonymity may fade quicker than expected.
Take a quick moment to consider tuning into: Chemomab Therapeutics Ltd. (Nasdaq: CMMB).
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential.
In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.
Chemomab has reported positive results from four clinical trials of nebokitug in patients.
Based on recent positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a PSC nebokitug Phase 3 trial.
The design calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential regulatory approval.
Data from the SPRING trial open label extension will be reported in the first quarter of 2025.
Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC.
Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND.
For Sources And More: CMMB Website. CMMB Presentation. -----
Consider These 4 Explosive Potential Catalysts For (Nasdaq: CMMB)
#1. A Low Float Could Create A Volatile Environment For CMMB.
CMMB’s low float, reported by Finviz at around 16.57Mn shares, could significantly impact its volatility.
A limited float often means sharper chart movements when new developments arise, whether good or bad.
If CMMB shares positive updates in early 2025, this characteristic might amplify market reactions.
The combination of a small float and potential news could create conditions for significantly more attention on CMMB quickly.
#2. A $7 Analyst Target May Suggest CMMB Is Undervalued At Current Chart Levels.
Maxim Group has established itself as a leading force in Wall Street research, particularly focusing on smaller, up-and-coming enterprises with significant growth potential.
Their expertise lies in analyzing and evaluating companies that are often overlooked by larger institutions.
Michael Okunewitch, a biotechnology sector analyst at Maxim Group, recently published a report on Chemomab Therapeutics. As of March 21, 2025, Okunewitch has projected a valuation of $7.00 for CMMB.
Based on Okunewitch's analysis, the company's value could potentially increase by more than 400% from its closing valuation Wednesday.
#3. Chemomab Presents New Evidence Supporting nebokitug As A Promising Therapy For Systemic Sclerosis.
Chemomab Therapeutics recently presented new data at CORA 2025 supporting the potential of nebokitug (CM-101) as a treatment for systemic sclerosis (SSc), a lethal autoimmune disease with no approved disease-modifying therapies.
The study identified specific immune cell populations with altered CCR3 expression linked to SSc, further strengthening the scientific rationale for targeting CCL24 with nebokitug.
This presentation adds to the growing body of evidence supporting nebokitug's potential in SSc treatment, building upon previous positive results from the Phase 2 SPRING trial in PSC patients and paving the way for a planned Phase 2 trial in SSc, for which Chemomab has an open U.S. IND.
#4. Chemomab Achieves Crucial Breakthrough: FDA Endorses Streamlined Phase 3 Trial Design For Key Drug Candidate.
Chemomab Therapeutics achieved a significant milestone by successfully completing its End-of-Phase 2 Meeting with the FDA, aligning on a streamlined path to potential regulatory approval for nebokitug (CM-101) in Primary Sclerosing Cholangitis (PSC).
The FDA agreed to a single pivotal Phase 3 trial design that eliminates the need for liver biopsies and additional confirmatory studies, potentially accelerating the timeline to full approval.
This development positions nebokitug to potentially become the first FDA-approved treatment for PSC, a debilitating disorder with no currently approved therapies, and provides regulatory clarity in the field for the first time. -----
Coverage is officially initiated on Chemomab Therapeutics Ltd. (Nasdaq: CMMB).
I'll be in touch with updates when necessary. Talk again shortly.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/26/2025 and ending on 03/27/2025 to publicly disseminate information about (CMMB:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (CMMB:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/cmmb/#details | 
0 Response to "Biotech Alert (Nasdaq: CMMB) Is Developing Innovative Therapeutics (4 Potential Catalysts)"
Post a Comment